1
|
Petrescu AM, Pirici ND, Ruxanda AI, Vasile L, Pîrșcoveanu M, Paitici Ș, Petrescu GS, Munteanu AC, Matei RA, Dumitrache D, Donoiu A, Mogoantă SȘ. Aggressive Male Breast Cancer-Clinical and Therapeutic Aspects Correlated with the Histopathological Examination: A Case Report and Literature Review. MEDICINA (KAUNAS, LITHUANIA) 2023; 59:2167. [PMID: 38138270 PMCID: PMC10744383 DOI: 10.3390/medicina59122167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/21/2023] [Revised: 12/01/2023] [Accepted: 12/11/2023] [Indexed: 12/24/2023]
Abstract
Breast cancer is often seen as a disease that occurs in women, but it can also appear in men in a very small percentage, below 1%. Men have a minimal amount of breast tissue compared to women, which has the potential to become malignant in a similar way to women, although much less frequently. A patient presented with advanced local invasion due to the low amount of breast tissue, with the tumor quickly invading the adjacent structures. Histopathological and immunohistochemical examinations have an extremely important role in the pathology of breast cancer. Given that male breast cancer is rare and there are not enough surgeons specializing in breast surgery in our country, there is a lack of experience in the management and early diagnosis of this type of cancer, which will be highlighted in this article.
Collapse
Affiliation(s)
- Ana-Maria Petrescu
- Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania; (A.-M.P.); (R.-A.M.)
- 3rd General Surgery Clinic, Emergency County Hospital, 200642 Craiova, Romania; (A.-I.R.); (L.V.); (M.P.); (A.C.M.); (D.D.); (S.-Ș.M.)
| | - Nicolae-Daniel Pirici
- Department of Research Methodology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania;
| | - Anca-Ileana Ruxanda
- 3rd General Surgery Clinic, Emergency County Hospital, 200642 Craiova, Romania; (A.-I.R.); (L.V.); (M.P.); (A.C.M.); (D.D.); (S.-Ș.M.)
- Department of Surgery, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
| | - Liviu Vasile
- 3rd General Surgery Clinic, Emergency County Hospital, 200642 Craiova, Romania; (A.-I.R.); (L.V.); (M.P.); (A.C.M.); (D.D.); (S.-Ș.M.)
- Department of Surgery, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
| | - Mircea Pîrșcoveanu
- 3rd General Surgery Clinic, Emergency County Hospital, 200642 Craiova, Romania; (A.-I.R.); (L.V.); (M.P.); (A.C.M.); (D.D.); (S.-Ș.M.)
- Department of Surgery, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
| | - Ștefan Paitici
- 3rd General Surgery Clinic, Emergency County Hospital, 200642 Craiova, Romania; (A.-I.R.); (L.V.); (M.P.); (A.C.M.); (D.D.); (S.-Ș.M.)
- Department of Surgery, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
| | - Gabriel-Sebastian Petrescu
- Department of Oral and Maxillofacial Surgery, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania;
| | - Alexandru Claudiu Munteanu
- 3rd General Surgery Clinic, Emergency County Hospital, 200642 Craiova, Romania; (A.-I.R.); (L.V.); (M.P.); (A.C.M.); (D.D.); (S.-Ș.M.)
- Department of Surgery, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
| | - Ramona-Andreea Matei
- Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania; (A.-M.P.); (R.-A.M.)
| | - Daniel Dumitrache
- 3rd General Surgery Clinic, Emergency County Hospital, 200642 Craiova, Romania; (A.-I.R.); (L.V.); (M.P.); (A.C.M.); (D.D.); (S.-Ș.M.)
| | - Andreas Donoiu
- Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania; (A.-M.P.); (R.-A.M.)
- 3rd General Surgery Clinic, Emergency County Hospital, 200642 Craiova, Romania; (A.-I.R.); (L.V.); (M.P.); (A.C.M.); (D.D.); (S.-Ș.M.)
| | - Stelian-Ștefăniță Mogoantă
- 3rd General Surgery Clinic, Emergency County Hospital, 200642 Craiova, Romania; (A.-I.R.); (L.V.); (M.P.); (A.C.M.); (D.D.); (S.-Ș.M.)
- Department of Surgery, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
| |
Collapse
|
2
|
Ediz C, Akan S, Huseyin Tavukcu H, Kayhan ME, Yilmaz O. Prognosis of primary or metachronous prostate cancer in multiple primary genitourinary cancers; a single center experience with long-term results. Aging Male 2021; 24:37-41. [PMID: 34338118 DOI: 10.1080/13685538.2020.1817368] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
Abstract
OBJECTIVE This study aims to analyze the challenges, approaches and long-term results of primary or metachronous prostate cancer (PCa) in cases with multiple primary genitourinary cancers. METHODOLOGY A total of 17 patients were included in the study. Patients with multiple primary genitourinary cancers were divided into two groups according to the diagnosis of primary or metachronous PCa as group 1 and group 2. RESULTS The median age of patients was similar in both groups. The median smoking status (pack-years) was higher in group 2 than group 1. The median prostate-specific antigen (PSA) level was higher in group 1 than group 2. The median follow-up time from primary to the metachronous tumour was higher in group 1 than group 2. The rate of recurrence in PCa was higher in group 1 than group 2. No statistically significant difference was observed in terms of patients' age, smoking status, PSA levels at diagnosis of PCa and biochemical recurrence or metastasis between the two groups (p > 0.05). CONCLUSION Primary PCa cases may progress more aggressively than metachronous PCa cases. Biochemical recurrence and metastasis may be less threatening in metachronous PCa cases than primary cases. Therefore, aggressive treatment can be avoided for metachronous PCa cases.
Collapse
Affiliation(s)
- Caner Ediz
- Department of Urology, Sultan Abdulhamid Han Education and Research Hospital, Istanbul, Turkey
| | - Serkan Akan
- Department of Urology, Sultan Abdulhamid Han Education and Research Hospital, Istanbul, Turkey
| | - Hasan Huseyin Tavukcu
- Department of Urology, Sultan Abdulhamid Han Education and Research Hospital, Istanbul, Turkey
| | - Muhammed Esad Kayhan
- Department of Urology, Sultan Abdulhamid Han Education and Research Hospital, Istanbul, Turkey
| | - Omer Yilmaz
- Department of Urology, Sultan Abdulhamid Han Education and Research Hospital, Istanbul, Turkey
| |
Collapse
|
3
|
Liang L, Cheng Y, Qi F, Zhang L, Cao D, Cheng G, Hua L. A Comparative Study of Prostate Cancer Detection Rate Between Transperineal COG-TB and Transperineal FUS-TB in Patients with PSA ≤20 ng/mL. J Endourol 2020; 34:1008-1014. [PMID: 32600058 DOI: 10.1089/end.2020.0276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Background: The combination of prebiopsy MRI and transperineal targeted biopsies is being increasingly used to obtain tissues from patients with suspected prostate cancer (PCa). Objective: To investigate the difference in PCa detection rate between transperineal cognitive fusion TB (COG-TB) and transperineal software fusion TB (FUS-TB). Participants: The present study included 163 male patients with suspected PCa who had not undergone prostate biopsy, had a prostate-specific antigen (PSA) level of ≤20 ng/mL, and had been examined by bi-parameter MRI and confirmed to have prostate nodules by prostate imaging reporting and data system version 2 (PI-RADS V2) scores ≥3 (from December 3, 2018 to October 7, 2019). Intervention: Seventy-one patients underwent transperineal COG-TB, and 92 patients underwent transperineal FUS-TB. The detection rate of the first four needles was compared. Results: No significant difference was found in the overall detection rate of PCa between COG-TB and FUS-TB (60.56% vs 51.08%, p = 0.228). This result was consistent even after stratifying by PI-RADS score. There was also no significant difference between COG-TB and FUS-TB in the detection rate of clinically significant PCa (p = 0.641). Moreover, COG-TB and FUS-TB showed no difference in the detection rate of PCa with different Gleason scores. Conclusions: In patients with suspected PCa with PSA ≤20 ng/mL and PI-RADS ≥3, FUS-TB was comparable to COG-TB in the detection rate of PCa.
Collapse
Affiliation(s)
- Linghui Liang
- Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Yifei Cheng
- Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Feng Qi
- Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Lei Zhang
- Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Dongliang Cao
- Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Gong Cheng
- Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Lixin Hua
- Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| |
Collapse
|